DECNUPAZ is an IgG1-based ADC designed to target CD123, a protein overexpressed on BPDCN cells.1-3
DECNUPAZ delivers a payload that is a member of the IGN* class of cytotoxic molecules.1
*IGN=indolinobenzodiazepine pseudodimer
The IgG1 antibody portion of DECNUPAZ targets and binds to CD123 with high affinity. While DECNUPAZ binds with high affinity to CD123, it may also affect healthy cells.1,4
Once bound, DECNUPAZ is internalized. The peptide linker undergoes lysosomal degradation, releasing the IGN payload (FGN849).1,5
The IGN payload then alkylates DNA, which leads to single‑strand breaks, making it first in class.1,6
These single-strand breaks may trigger cell cycle arrest and apoptosis, leading to cell death.1
Because of the way DECNUPAZ works, it has been shown to have adverse reactions. The most common Grade 3–4 laboratory abnormalities seen with DECNUPAZ (≥10%) were decreased neutrophils, platelets, lymphocyte count, white blood cells, hemoglobin, and increased glucose.1
The IGN* payload has shown potency against tumor cells and potentially less cytotoxicity to normal bone marrow progenitors in a descriptive pre‑clinical study.1,4
ADC=antibody-drug conjugate; BPDCN=blastic plasmacytoid dendritic cell neoplasm; DNA=deoxyribonucleic acid; IgG1=immunoglobulin G1
DECNUPAZ™ (pivekimab sunirine-pvzy) is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Hepatotoxicity, Including Hepatic VOD
Infusion-Related Reactions
Edema
Sulfite Allergic Reactions
Embryo-Fetal Toxicity
Please see full Prescribing Information, including BOXED WARNING, or visit https://www.rxabbvie.com
US-PVEK-260092
REFERENCES:
1. DECNUPAZ [package insert]. North Chicago, IL: AbbVie Inc.
2. Pemmaraju N, Deconinck E, Mehta P, et al. Recent advances in the biology and CD123-directed treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Lymphoma Myeloma Leuk. 2024;24(4):e130-e137.
3. Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):16-23.
4.Kovtun Y, Jones GE, Adams S, et al. Blood Adv. 2018;2(8):848-858. doi:10.1182/bloodadvances.2018017517
5. Miller ML, Shizuka M, Wilhelm A, et al. A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody-drug conjugates (ADCs). Mol Cancer Ther. 2018;17(3):650-660.
6. Pemmaraju N, Marconi G, Montesinos P, et al. Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2026;00:1-13.
